Today The Peel Hunt Reaffirms  Buy Rating for Vectura Group PLC (VEC)

Today The Peel Hunt Reaffirms  Buy Rating for Vectura Group PLC (VEC)

Vectura Group PLC (LON:VEC)‘s stock had its ” buy” rating restated by investment analysts at Peel Hunt in a research note issued on Wednesday. They presently have a GBX 200 ($2.50) price target on the stock. Peel Hunt’s price objective would suggest a potential upside of 47.82% from the company’s current price.

Other research analysts have also recently issued research reports about the stock. Stifel Nicolaus reiterated a “buy” rating and issued a GBX 225 ($2.81) target price on shares of Vectura Group PLC in a research note on Tuesday. Numis Securities Ltd reiterated a “buy” rating and issued a GBX 252 ($3.14) target price on shares of Vectura Group PLC in a research note on Wednesday. N+1 Singer cut their target price on shares of Vectura Group PLC from GBX 208 ($2.60) to GBX 202 ($2.52) and set a “buy” rating for the company in a research note on Tuesday, December 20th. Finally, J P Morgan Chase & Co reiterated an “overweight” rating and issued a GBX 230 ($2.87) target price on shares of Vectura Group PLC in a research note on Thursday, November 24th. Seven equities research analysts have rated the stock with a buy rating, Vectura Group PLC has an average rating of “Buy” and a consensus target price of GBX 220.50 ($2.75).

Shares of Vectura Group PLC (LON:VEC) opened at 132.46 on Wednesday. Vectura Group PLC has a 1-year low of GBX 122.90 and a 1-year high of GBX 183.70. The stock’s 50 day moving average price is GBX 138.11 and its 200 day moving average price is GBX 140.89. The company’s market capitalization is GBX 761.25 million.

Vectura Group PLC Company Profile

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Related posts

Leave a Comment